LV10386B - Pharmaceutical composition and process for the preparation thereof - Google Patents

Pharmaceutical composition and process for the preparation thereof Download PDF

Info

Publication number
LV10386B
LV10386B LVP-92-547A LV920547A LV10386B LV 10386 B LV10386 B LV 10386B LV 920547 A LV920547 A LV 920547A LV 10386 B LV10386 B LV 10386B
Authority
LV
Latvia
Prior art keywords
inhibitor
mao
composition according
group
phenyl
Prior art date
Application number
LVP-92-547A
Other languages
English (en)
Latvian (lv)
Other versions
LV10386A (lv
Inventor
Magyar Kalman Dr
Gaal Jozsef Dr
Sziraki Istvan Dr
Lengyel Jozsef
Anna Z Szabo
Marmarosi-Nee-Kellner Katalin
Hermecz Istvan
Szatmari Istvan Dr
Torok Zoltan Dr
Kirmiczy Puter
Original Assignee
Chinoin Gyegyszer S Vegy Szeti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyegyszer S Vegy Szeti filed Critical Chinoin Gyegyszer S Vegy Szeti
Publication of LV10386A publication Critical patent/LV10386A/xx
Publication of LV10386B publication Critical patent/LV10386B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LVP-92-547A 1991-12-20 1992-12-20 Pharmaceutical composition and process for the preparation thereof LV10386B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU914060A HUT63579A (en) 1991-12-20 1991-12-20 Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes

Publications (2)

Publication Number Publication Date
LV10386A LV10386A (lv) 1995-02-20
LV10386B true LV10386B (en) 1995-12-20

Family

ID=10966728

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-547A LV10386B (en) 1991-12-20 1992-12-20 Pharmaceutical composition and process for the preparation thereof

Country Status (27)

Country Link
US (1) US5589513A (fr)
EP (1) EP0617615A1 (fr)
JP (1) JPH07502730A (fr)
KR (1) KR940703655A (fr)
AU (1) AU677170B2 (fr)
BG (1) BG98827A (fr)
BR (1) BR9206950A (fr)
CA (1) CA2125776A1 (fr)
CZ (1) CZ147494A3 (fr)
EC (1) ECSP930933A (fr)
EE (1) EE03015B1 (fr)
FI (1) FI942932A (fr)
HU (2) HUT63579A (fr)
IL (1) IL104150A (fr)
LT (1) LT3119B (fr)
LV (1) LV10386B (fr)
MY (1) MY111055A (fr)
NO (1) NO942303D0 (fr)
NZ (1) NZ246384A (fr)
PH (1) PH31073A (fr)
PL (1) PL172048B1 (fr)
RO (1) RO115785B1 (fr)
RU (1) RU2125448C1 (fr)
SI (1) SI9200404A (fr)
SK (1) SK74494A3 (fr)
WO (1) WO1993012775A1 (fr)
ZA (1) ZA929883B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
DE4432610C1 (de) * 1994-09-13 1996-02-01 Knoll Ag Verfahren zur Herstellung von Selegilin-Hydrochlorid
AU723047B2 (en) 1995-02-10 2000-08-17 University Of Toronto Innovations Foundation, The Deprenyl compounds for treatment of glaucoma
JP4499208B2 (ja) * 1998-10-29 2010-07-07 株式会社フジモト・コーポレーション 新規な光学活性アミノペンタン誘導体
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HUP9902482A2 (hu) * 1999-07-22 2002-04-29 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. P-fluoro-selegilin alkalmazása neuroprotektív gyógyszerkészítmények előállítására
EP2053033A1 (fr) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Composants à utiliser dans l'imagerie, le diagnostic et/ou le traitement des maladies du système nerveux central ou des tumeurs
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
DE102009045056A1 (de) * 2009-09-28 2011-03-31 Henkel Ag & Co. Kgaa Fleckenvorbehandlungsmittel
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
WO2016033549A2 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
DE3764144D1 (de) * 1986-04-16 1990-09-13 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
CA2037178A1 (fr) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Composition pharmaceutique a base de deprenyl/l-dopa/carbidopa
GB9011767D0 (en) * 1990-05-25 1990-07-18 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US5169868A (en) * 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals

Also Published As

Publication number Publication date
FI942932A0 (fi) 1994-06-17
CZ147494A3 (en) 1995-01-18
LV10386A (lv) 1995-02-20
HU914060D0 (en) 1992-03-30
RO115785B1 (ro) 2000-06-30
HUT63579A (en) 1993-09-28
US5589513A (en) 1996-12-31
ECSP930933A (es) 1994-04-20
ZA929883B (en) 1994-05-16
BR9206950A (pt) 1995-11-28
PH31073A (en) 1998-02-05
CA2125776A1 (fr) 1993-07-08
EE03015B1 (et) 1997-08-15
IL104150A (en) 1997-11-20
NZ246384A (en) 1996-02-27
AU3265293A (en) 1993-07-28
RU2125448C1 (ru) 1999-01-27
PL172048B1 (pl) 1997-07-31
JPH07502730A (ja) 1995-03-23
LTIP249A (en) 1994-07-15
HU211478A9 (en) 1995-11-28
SK74494A3 (en) 1995-01-12
LT3119B (en) 1994-12-27
SI9200404A (en) 1993-06-30
WO1993012775A1 (fr) 1993-07-08
NO942303D0 (no) 1994-06-17
MY111055A (en) 1999-08-30
FI942932A (fi) 1994-06-17
KR940703655A (ko) 1994-12-12
BG98827A (en) 1995-06-30
AU677170B2 (en) 1997-04-17
EP0617615A1 (fr) 1994-10-05
NO942303L (fr) 1994-08-17

Similar Documents

Publication Publication Date Title
US5589513A (en) Pharmaceutical composition and process for the preparation thereof
Birkmayer et al. Implications of combined treatment with'Madopar'and L-deprenil in Parkinson's disease: a long-term study
KR960000430B1 (ko) 산화에 안정한 약제 조성물
EP2892518B1 (fr) Nouvelles approches thérapeutiques pour le traitement de la maladie de parkinson
RU2140266C1 (ru) Фармацевтическая композиция с регулируемым выделением на основе одной или нескольких фармацевтически приемлемых солей гамма-гидроксимасляной кислоты и способ ее получения
AU643201B2 (en) Use of eicosapentaenoic acid for the treatment of cachexia
US9248111B2 (en) Therapeutic approaches for treating parkinson's disease
Ekstedt et al. Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?
IE843149L (en) Synergistic pharmaceutical compositions
CZ2003497A3 (cs) �@Aminoalkylcyklohexanová sloučenina a její použití
Yu et al. Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine‐like monoamine oxidase B inhibitors
CA1261272A (fr) Combinaison de produit a dihydropyridine
KR20010042765A (ko) Ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 그리고 ｎａｄｈ및/또는 ｎａｄｐｈ가 포함되는 조성물
JPH02500596A (ja) 医薬組成物
ZA200507497B (en) Therapeutic and/or preventive agent for chronic skin disease
MXPA00012248A (es) Incrementadores de acetilcolina.
EP0754455A1 (fr) Compositions pharmaceutiques a base d'aminomethylindoles pour leur application therapeutique en tant que neuroprotecteurs dans les maladies de parkinson et d'alzheimer
JP3394257B2 (ja) パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用
Caccia et al. Interaction of (+)‐amphetamine with cerebral dopaminergic neurones in two strains of mice, that show different temperature responses to this drug
Vidaluc MPTP as a molecular paradigm for neurodegeneration. A review of its connections with relevant molecules
US4046917A (en) Method of treating migraine
Ondo Investigational pharmacological treatments for Parkinson’s disease
JP2006516267A (ja) コリンエステラーゼ阻害剤中毒の医薬的予防方法並びにこれに適する活性物質および医薬
Thomsen et al. Preclinical and clinical studies with galanthamine
MXPA00006353A (en) Remedy for neurodegenerative diseases___________________________